Assessment of non-alcoholic fatty liver disease risk in patients with type 2 diabetes mellitus by leptine and triglyceride levels (mathemathic model)

Authors

  • Plohotnichenko O. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Gorshunska M. Y. Kharkiv Postgraduate Medical Academy, Kharkiv, Ukraine
  • Tyzhnenko T. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Krasova N. S. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Leshchenko Zh. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Gladkih A. I. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Poltorak V. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2018.4.01

Keywords:

type 2 diabetes mellitus, non-alcoholic fatty liver disease, triglycerides, leptin, discriminant analysis

Abstract

It was examined repeatedly patients with type 2 diabetes mellitus at the age within 33 and 65 years. It was established a significant increase in leptin and triglyceride levels in group of patients with non-alcoholic fatty liver disease. These indicators can be used as prognostic factors for the pathology risk assessment. Discriminant analysis with calculation of sensitivity, specificity, prognostic value of the positive and negative results and the accuracy index was conducted. It has been developed the diagnostic model for the identification of individuals with non-alcoholic fatty liver disease development risk among the type 2 diabetic patients based on the combined pattern of triglyceridemia and leptinemia, which will improve the quality of diagnosis and forming groups for preventive therapy.

References

Traussnigg S, Kienbacher C, Halilbasic E, et al. Dig Dis 2015; 33 (4): 598-607. doi: http://doi.org/10.1159/000375353.

Araujo AR, Rosso N, Bedogni G, et al. Liver International 2018; 38 (1): 47-51. doi: http://doi.org/10.1111/liv.13643.

Wojcik-Cichy K, Koślińska-Berkan E, Piekarska A. Clin Exp Hepatol 2018; 4: 1-6. doi: http://doi.org/10.5114/ceh.2018.73155.

Zhou YY, Zhou XD, Wu ShJ, et al. Hepatol Commun 2018; 2: 376-392. doi: http://doi.org/10.1097/MOL.0000000000000535.

Polimeni L, Del Ben M, Baratta F, et al. World J Hepatol 2015; 7 (10): 1325-1336. doi: http://doi.org/10.4254/wjh.v7.i10.1325.

Kostic'ka IO. Ukr Med Chasopys 2010; 4 (78): 84-90.

Polyzos SA, Kountouras J, Mantzoros CS. Metabolism 2016;65 (8): 1062-1079. doi: http://doi.org/10.1016/j.metabol.2015.11.006.

Boutari Chrysoula, Nikolaos Perakakis, Christos Socrates Mantzoros. Endocrinol Metab 2018; 33 (1): 33-43. doi: http://doi.org/10.3803/EnM.2018.33.1.33.

Adolph TE, Grander Ch, Grabherr F, Tilg H. Int J Mol Sci 2017; 18: 1649. doi: http://doi.org/10.3390/ijms18081649.

Meek TH, Morton GJ. Diabetologia 2016; 59: 928-932. doi: http://doi.org/10.1007/s00125-016-3898-3.

Petta S, Gastaldelli A, Rebelos E, et. al. Int J Mol Sci 2016; 17: 2082. doi: http://doi.org/10.3390/ijms17122082.

Angulo P, Alba LM, Petrovic LM, et al. J Hepatol 2004;41: 943-949.

Abiru S, Migita K, Maeda Y, et al. Liver Int 2006; 26 (1): 39-45.

Rotundo L, Persaud A, Feurdean M, et al. Clin Mol Hepatol 2018. doi: http://doi.org/10.3350/cmh.2018.0011.

Livzan MA, Lapteva IV, Miller TS. Eksp Klin Gastroenterol 2014; 8: 27-33.

Cernea S, Roiban AL, Both E, Huţanu A. Diabetes Metab Res Rev 2018: e3050. doi: http://doi.org/10.1002/dmrr.3050.

Urbanovych AM. Eksperym ta klinich fiziologija i biohimija 2010; 1: 57-63.

Matthews DR, Hoske JP, Rudensk AS, et al. Diabetologia 1985; 28: 412-419.

Katz A, Nambi SS, Mather K, et al. J Clin Endocr Metab 2000; 85: 2402-2410.

Halafjan AA. STATISTICA 6. Statisticheskij analiz dannyh, Moskva, 2007: 512 p.

Field A. Discovering Statistics Using SPSS. 2nd ed. 2005: 781 p.

Banerdzhi A. Medicinskaja statistika ponjatnym jazykom, Moskva, 2007: 288 p.

Wang Y, Zhou M, Lam KSL, Xu A. Arq Bras Endocrinol Metab 2009; 53: 201-212.

Ratziu V, Bellentani S, Cortez-Pinto H, et al. J Hepatol 2010; 53: 372-384. doi: http://doi.org/10.1016/j.jhep.2010.04.008.

Shou-Wu Lee, Sheng-Shun Yang, Teng-Yu Lee, et al. J Adv Nutr Hum Metab 2016; 2: e1483-1489.

Fraser A, Thingaard M, Christensen K. Liver Int 2009; 29: 1494-1499. doi: http://doi.org/10.1111/j.1478-3231.2009.02090.x.

Mofrad P, Contos MJ, Haque M, et al. Hepatology 2003;37 (6): 1286-1292.

Cohen DE. The Liver: Biology and Pathobiology, Fifth Edition, Oxford, 2009: 271-285.

Musso G, Gambino R, Cassader PM. Lipid Res 2013; 52: 175-191. doi: http://doi.org/10.1016/j.plipres.2012.11.002.

Feldstein AE, Werneburg NW, Canbay A, et al. Hepatology 2004; 40: 185-194.

Yamaguchi K, Yang L, McCall S, et al. Hepatology 2008; 47: 625-635.

Browning JD, Horton JD. J Clin Invest 2004; 114: 147-152.

Min H-K, Kapoor A, Fuchs M, et al. Cell Metabolism 2012; 15 (5): 665-674. doi: http://doi.org/10.1016/j.cmet.2012.04.004.

Baratta M. Med Sci Monit 2002; 8: 282-292.

Petta S, Vanni E, Bugianesi E. Liver Int 2015; 35: 1566-1573. doi: http://doi.org/10.1111/liv.12584.

Downloads

Published

2021-08-17

How to Cite

Plohotnichenko, O. A., Gorshunska, M. Y. ., Tyzhnenko, T. V. ., Krasova, N. S. ., Leshchenko, Z. A. ., Gladkih, A. I. ., & Poltorak, V. V. (2021). Assessment of non-alcoholic fatty liver disease risk in patients with type 2 diabetes mellitus by leptine and triglyceride levels (mathemathic model). Problems of Endocrine Pathology, 66(4), 7-15. https://doi.org/10.21856/j-PEP.2018.4.01

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 > >>